MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Organogenesis Holdings Market Cap 2011-2026 | ORGO
As of March 24, 2026 Organogenesis Holdings has a market cap of $ 319 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Organogenesis Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 415 M | 475 M | 298 M | 1.19 B | 811 M | 437 M | 946 M | 92.9 M | 78.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.19 B | 78.2 M | 527 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
142 M | $ 0.95 | -2.04 % | $ 102 M |  Canada |
 |
Aurora Cannabis
ACB
|
915 M | $ 3.29 | -0.61 % | $ 86.3 M | Canada |
 |
China Pharma Holdings
CPHI
|
4.54 M | $ 0.63 | - | $ 11 M |  China |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
3.63 B | $ 2.51 | -0.31 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
139 M | $ 7.96 | -1.12 % | $ 408 M | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 22.63 | -0.09 % | $ 1.05 B | USA |
 |
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 3.15 | 3.28 % | $ 44.3 M | USA |
 |
Rockwell Medical
RMTI
|
35.5 M | $ 1.05 | 2.45 % | $ 24.5 M | USA |
 |
Bausch Health Companies
BHC
|
3.38 B | $ 4.98 | -2.35 % | $ 1.82 B | Canada |
 |
Solid Biosciences
SLDB
|
623 M | $ 6.9 | -3.36 % | $ 604 M | USA |
 |
Sundial Growers
SNDL
|
889 K | $ 1.36 | - | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 2.39 | -6.13 % | $ 2.97 M | USA |
 |
Harrow Health
HROW
|
1.93 B | $ 35.27 | 3.74 % | $ 1.3 B | USA |
 |
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | USA |
 |
Tilray
TLRY
|
1.19 B | $ 6.43 | -0.31 % | $ 3.97 B | Canada |
 |
Evolus
EOLS
|
271 M | $ 4.61 | -1.6 % | $ 297 M | USA |
 |
Veru
VERU
|
108 M | $ 2.3 | - | $ 310 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 6.06 | 3.41 % | $ 239 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 13.43 | 1.02 % | $ 16.1 B | USA |
 |
OrganiGram Holdings
OGI
|
382 M | $ 1.36 | - | $ 402 M | Canada |
 |
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
82.8 M | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 0.88 | 0.79 % | $ 43.9 M | USA |
 |
TherapeuticsMD
TXMD
|
23.9 M | $ 2.35 | 1.73 % | $ 24.5 M | USA |
 |
cbdMD
YCBD
|
1.68 M | $ 0.78 | 2.25 % | $ 3.36 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
1.96 B | $ 9.64 | 0.68 % | $ 1.34 B | USA |
 |
Assertio Holdings
ASRT
|
75.4 M | $ 15.21 | 8.64 % | $ 97.4 M | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |